Blood Advances · 2019 · 229 citations · 23 references
Life SciencesPharmacologyPharmacotherapyCancer PharmacologyImmunoregulationImmunotherapyCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesEffector T Cell FunctionT Cell Activation ControlT Cell BiologyToxicity ManagementCar T-cell Toxicity ManagementCytokine Secretion RegulationCytokine-mediated T Cell ResponsesImmune Cell CytotoxicityT Cell CytotoxicityT Cell-mediated CytotoxicityT-cell Mediated ToxicityT-cell Therapy
Key Points Dasatinib potently and reversibly suppresses CAR-T cell cytotoxicity, cytokine secretion, and proliferation. Dasatinib could be repurposed as a safety switch to mitigate CAR-mediated toxicity in patients.
23
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text
Medicine, Hematology, Oncology +16
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al. · New England Journal of Medicine · 2018 · 5.6K citations · Full text
Medicine, Hematology, Oncology +17
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee, Rebecca Gardner, David Porter et al. · Blood · 2014 · 2.8K citations
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Journal of Clinical Investigation · 2016 · 2.1K citations · Full text
Medicine, Immunology, Oncology +17